ST LOUIS (MD Consult) - On August 24, 2009, Sanofi-aventis announced that the US Food and Drug Administration (FDA) has approved Xyzal (levocetirizine dihydrochloride) for the treatment of symptoms of perennial allergic rhinitis (indoor allergies) and chronic idiopathic urticaria (chronic hives) in children aged 6 months and older. This new approval also allows for use of the product in children aged 2 years and older with symptoms of seasonal allergic rhinitis (outdoor allergies). Xyzal was previously approved to treat patients aged 6 years and older with symptoms of perenniel and seasonal allergic rhinitis or with chronic idiopathic urticaria.
Xyzal is a once-daily prescription antihistamine in both tablet and liquid formulations.
In patients aged 12 years and older, adverse effects may include somnolence, fatigue, sore throat, and dry mouth. In children aged 6 to 12 years, untoward effects may include fever, cough, somnolence, and epistaxis. In children aged 1 to 5 years, adverse effects may include fever, diarrhea, vomiting, and ear infections. In infants aged 6 to 11 months, undesirable effects may include diarrhea and constipation.
圣路易斯(MD Consult)——2009年8月24日，赛诺菲-安万特公司宣布：美国食品药品管理局(FDA)已经批准Xyzal(商品名：优泽；通用名：盐酸左旋西替利嗪)用于年龄在6个月以上儿童的常年性变应性鼻炎以及慢性特发性荨麻疹的症状治疗。该最新认证还允许使用优泽治疗年龄在2岁以上儿童的季节性过敏性鼻炎(室外过敏)症状。此前，优泽被批准用于年龄在6岁以上患儿的常年性和季节性过敏性鼻炎或慢性特发性荨麻疹的症状治疗。
优泽是一种处方类抗组胺药，每日用药一次，分为片剂和液剂。
该药物在12岁以上患儿的副作用包括嗜睡、乏力、口干及咽喉疼痛。在6~12岁儿童，其副作用可能包括发烧、咳嗽、嗜睡和鼻出血。发烧、腹泻、呕吐、耳部感染等副作用可发生于1~5岁的患儿。而在6~11个月婴儿的副作用可能包括腹泻和便秘。
